Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia - Full Text View

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia

This study has been completed.

Sponsored by:	Fairview University Medical Center
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00005891

Purpose

OBJECTIVES:

I. Determine the effectiveness of moderate dose cyclophosphamide and total lymphoid radiotherapy in terms of improving the survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with Fanconi's aplastic anemia.

Condition	Intervention
Fanconi's Anemia	Drug: cyclophosphamide Procedure: Allogeneic Bone Marrow Transplantation

MedlinePlus related topics:

Anemia Bone Marrow Transplantation

ChemIDplus related topics:

Cyclophosphamide

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Study Start Date:

March 2000

Detailed Description:

PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 2 hours on day -6 through -3 and total lymphoid radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.

Patients are followed for at least 100 days.

Eligibility

Ages Eligible for Study:	up to 54 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Diagnosis of severe aplastic anemia with the typical phenotype of Fanconi's anemia: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
Family history of Fanconi's anemia
Histocompatible related donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005891

Locations


United States, Minnesota
	Fairview University Medical Center
	Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Fairview University Medical Center

Investigators


Study Chair:	Daniel J. Weisdorf	Fairview University Medical Center

More Information

Study ID Numbers:	199/15099, UMN-MT-1982-10, UMN-MT-8210
First Received:	June 2, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00005891
Health Authority:	Unspecified

Keywords provided by Office of Rare Diseases (ORD):

Fanconi's Anemia

aplastic anemia

hematologic disorders

rare disease

Study placed in the following topic categories:

Metabolic Diseases

Fanconi's anemia

Genetic Diseases, Inborn

Hematologic Diseases

Fanconi Anemia

Rare Diseases

Anemia, Aplastic

Anemia

Cyclophosphamide

Metabolic disorder

Aplastic anemia

Bone Marrow Diseases

Additional relevant MeSH terms:

Immunologic Factors

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

DNA Repair-Deficiency Disorders

Physiological Effects of Drugs

Immunosuppressive Agents

Pharmacologic Actions

Anemia, Hypoplastic, Congenital

Therapeutic Uses

Myeloablative Agonists

Antineoplastic Agents, Alkylating

Antirheumatic Agents

Alkylating Agents

ClinicalTrials.gov processed this record on October 10, 2008